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Human cancers represent complex structures, which display substantial inter- and intratumor heterogeneity in their
genetic expression and phenotypic features. However, cancers usually exhibit characteristic structural, physiologic,
and molecular features and display specific biological capabilities named hallmarks. Many of these tumor traits are
imageable through different imaging techniques. Imaging is able to spatially map key cancer features and tumor
heterogeneity improving tumor diagnosis, characterization, and management. This paper aims to summarize the
current and emerging applications of imaging in tumor biology assessment.
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 Tumors demonstrate substantial inter- and intratumor
heterogeneity in their biological features
 Imaging techniques may improve the assessment of
tumor-specific characteristics in clinical practice.
 Functional and molecular imaging techniques may
depict tumor heterogeneity.Introduction
Imaging techniques have emerged as exceptionally power-
ful, versatile, and precise tools for assessing relevant tumor
characteristics. Cancers usually display several structural,
physiologic, and molecular changes and common acquired
biological capabilities that can be evaluated with imaging
[1, 2]. Besides, tumors demonstrate substantial inter- and
intratumor heterogeneity in their biological features [3]. A
modern personalized oncologic approach requires a deeper
understanding of these cancer traits for being implemented
in patient care. Functional-molecular imaging (FMI) infor-
mation in addition to morphologic/anatomical changes
can simultaneously assess a multitude of biological cancer-
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the Creative Commons license, and indicate ifthe assessment of response to therapy [4]. Different
imaging techniques are useful for this role, including
dynamic contrast-enhanced MRI (DCE-MRI), DCE-
ultrasound (US), dynamic susceptibility contrast-
enhanced MRI (DSC-MRI), perfusion CT (PCT),
diffusion-weighted imaging (DWI), and magnetic reso-
nance spectroscopy (MRS) and spectroscopic imaging
(MRSI), arterial spin-labeling (ASL), blood oxygenation
level-dependent MR imaging (BOLD-MRI), elastography,
positron emission tomography (PET), or single-photon
emission computed tomography (SPECT) imaging (Fig. 1)
(Additional file 1: Table S1). These imaging techniques
enable the evaluation of unseen tumor characteristics by
conventional techniques improving tumor diagnosis and
management [4, 5]. In this ssetting, the biological and
physiological correlations of imaging parameters (which
depend on tumor type, imaging technique, and technical
questions) need to be established and the limitations and
possible pitfalls of every imaging technique must be
asessed. This paper aims to summarize the role of imaging
in the assessment of tumor biology.Imaging for the evaluation of tumor biology
Imaging techniques are increasingly being used to perform
a noninvasive assessment of tumor biology in clinical
practice. Imaging offers an adequate combination ofis distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
Fig. 1 Main imaging techniques in the evaluation of tumor biology and microenvinroment
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evaluating cancer phenotype in vivo at different levels [6].
Tumor macrostructural characteristics on imaging
Tumors are heterogeneous in nature and during malig-
nant transformation, their structural features change
substantially at different levels. Morphologic and struc-
tural differences between tumors are sometimes apparent
and classical subjective descriptors of these characteristics
(e.g., spiculated margin) are common. Tumor size and
volume are usually important features in tumor eva-
luation and may have prognostic value. However, diffe-
rent imaging techniques may improve the assessment
of tumor structure.
Tumor morphology
The morphologic phenotype of neoplasms is widely va-
riable; however, the presence of morphological features
typical of benign, borderline, or malignant tumors in-
creased the level of diagnostic confidence of radiologists.
In this setting, different imaging-based classification systems
(reporting and data system or -RADS) have been established
to standardize imaging reporting and data collection in
different organs, such as breast (BI-RADS), liver (LI-RADS),
lung (Lu-RADS), thyroid (TI-RADS), etc. [7–10]. These
-RADS lexicons include different morphological features(margin, shape, size, internal pattern, etc.) and provide
an estimated risk of malignancy. So, well-defined tumor
margins are considered an indicator of less infiltrative
behavior and, thus, lower aggressiveness. Besides, a
tumor morphologic phenotype may be associated to a
pathologic entity. For instance, cystic change in renal
cell carcinoma (RCC) has been mostly strongly asso-
ciated with the clear cell subtype and most recent data
indicate an overall favorable prognosis for the broad
spectrum of predominantly cystic RCCs [11]. Finally,
imaging features may be also associated to specific mu-
tations. In the case of clear cell RCC, well-defined tumor
margins were significantly more common among clear cell
RCCs with loss of von Hippel Lindau (VHL) gene function
[12]. The improvements in the computing capabilities of
radiologic equipment have allowed the development of
volume-based tumor measurements, which have demon-
strated to be more sensitive to tumor changes, more re-
producible and reliable than uni- or bi- dimensional
measurements [13]. Tumor volume has a prognostic value
in many tumor types and may improve tumor response
evaluation [14]. Finally, tumor growth pattern also seems
to be a prognostic significance in terms of overall survival.
For example, the presence of a fibrous capsule and the
characteristics of the tumor-liver interface are prognostic-
ally relevant in colorectal liver metastases [15].
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elasticity
Solid tumors are typically stiffer than the surrounding
healthy tissue. This feature is evaluated in clinical prac-
tice by palpation but elastographic imaging techniques
can also assess the elastic properties and stiffness of
tissues noninvasively.
Elastography provides knowledge about internal strains
induced in a soft material undergoing an axial stress.
There are two main imaging techniques for performing
elastography: US and MRI [16, 17].Technical features
The basic principle of elastography is to image the
propagation of mechanical waves within the tissue.
Stiffness, a biomechanical property of tissue, represents
its ability to resist deformation when subjected to a force.
Elastographic techniques evaluate these properties by a se-
quential process with three basic steps: (a) excitation
(stress) based on the application of mechanical waves for
deforming the tissue; (b) evaluating the tissue response
(strain); and (c) assessment of stiffness and
stiffness-related parameters displayed as quantitative para-
metric maps (elastograms) [16, 17]. Main elastographic
techniques are based on the evaluation of the shear waves,
which cause the oscillation of the particles of the medium
at a right angle to the direction of propagation.
Shear-wave speed is related to tissue stiffness and shows a
great variation depending on the structure and state of tis-
sue. Shear waves travel faster in stiff (tumor, inflamed, or
fibrotic) tissues and slower in soft (normal or fatty) tissues.
Recently, a quantitative estimation of tissue stiffness with-
out using mechanical vibrations (“virtual” elastography)
has been reported. This approach is based on the intra-
voxel incoherent motion (IVIM) contrast, which can be
converted quantitatively into shear modulus [18].
Biological bases of elastography
Cancer alters tissue mechanical properties. Solid tumors
are typically stiffer than the surrounding healthy tissue.
Several tumor characteristics may explain this feature,
including high cellularity, increased tumor stroma, and
increased interstitial pressure [17].Interpretation guidelines
The results of an elastographic exam are usually dis-
played by an elastogram, including an image represent-
ing the stiffnesses of the tissues superimposing on a
cross-sectional slice of the anatomy. Interpretation of ac-
quired images is based on different method of analysis
[16, 17]: (1) qualitative analysis including lesion com-
parison to a surrounding “normal” tissue as a reference,
(2) semiquantitative methods based on strain ratiosbetween different tissues included within the selected re-
gion of interest (ROI), and (3) quantitative parameters
with parametric maps.
Clinical value
Sonoelastography enables a more accurate evaluation of
the nature of superficial lesions situated in breast, thy-
roid, testicles, or lymph nodes (LNs). Elastography can
be also performed under endoscopic ultrasound (EUS)
guidance (Fig. 2). Main current clinical indications of
EUS elastography are solid pancreatic lesions, submuco-
sal gastrointestinal masses, and LNs. EUS elastography is
a reliable technique for the differentiation of solid pan-
creatic masses with a sensitivity of 95–97% and a specifi-
city of 67–76%, respectively [19]. In the case of the
accuracy of EUS-guided elastography for the differential
diagnosis of benign and malignant LNs, Xu et al. found
a sensitivity of 88% and a specificity of 85% [20]. Emer-
ging applications of EUs include prostate cancer (PCa)
and rectal tumors. Elastography has been demonstrated
to be superior to transrectal EUS alone in PCa, improv-
ing the specificity of prostate biopsies.
On its part, MRE has been tested in different tumor lo-
cations, including breast, prostate, liver, pancreas, or brain
suggesting that this technique may improve tumor detec-
tion and characterization [17]. Preliminary studies with
different therapies have showed an early decrease in tumor
stiffness and viscoelasticity (with no change in tumor ap-
parent tumor diffusion coefficient [ADC]), following treat-
ment, suggesting that MRE may be more sensitive than
DWI to early tumor response to therapy [17].
Tumor microstructure and composition on
imaging
Clinical imaging may provide information about micro-
structure, organization, composition, and histological
features in tumors [21–26]. Different imaging techniques
may be useful for this, including diffusion and
relaxation-weighted MRI, magnetization transfer (MT)
techniques, and spectral CT.
Diffusion-weighted imaging
Diffusion is a fundamental imaging technique that allows
a noninvasive assessment of tissue microstructure [21,
24, 25, 27–34].
Technical features
The extent of water molecule motion in tissues can be im-
aged by applying balanced gradients placed symmetrically
about a fat-suppressed T2-weighted sequence. The
weighting of the applied diffusion gradients is indicated
by their b value (measured in s/mm2), which depends
on the amplitude and duration of the gradients and the
time between them. In the absence of water molecules
Fig. 2 (See legend on next page.)
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Fig. 2 Rectal gastrointestinal stromal tumor (GIST) (white asterisk) in a 68-year-old man. a Optical colonoscopic image showed a rectal tumor
(arrow). b Endorectal ultrasonographic (US) image (right) with strain elastogram (left) showed that tumor (asterisk) appeared harder (more blue)
than the reference tissue on the elastogram. c A cut surface of the surgical specimen revealed a well-defined homogeneous aspect of the
submucosal mass (GIST)
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will cancel without a significant change in the mea-
sured signal intensity (SI). By comparison, in the case
of moving water molecules, their signal will not be
completely rephased by the second gradient, thus lead-
ing to a signal loss. Recent technological advances in
diffusion-weighted imaging (DWI) acquisition have facili-
tated the acquisition of multiple b values, including high
b values (> 1000 s/mm2), in clinical practice. Besides,
non-Gaussian analytic models of DWI (IVIM, diffu-
sion kurtosis imaging [DKI], stretched-exponential
model [SEM]) and vascular, extracellular, and re-
stricted diffusion for cytometry in tumors (VERDICT)Fig. 3 A 69-year-old man with Gleason 4 + 3 prostate cancer (white arrows
mono-exponential (a) intravoxel incoherent exponential model (IVIM)
imaging (DTI) (d). DWI can offer multiple parameters depending on th
apparent kurtosis (Kapp) with a different biological meaning. Biologica
analysis is not entirely clear and their clinical value may depend on tumwere proposed to more closely reflect the distribution
of physiologic and pathologic characteristics of tissues,
including cellularity, microcirculation, and heterogeneity
(Fig. 3). The IVIM model assumes a bi-exponential
decay of signal with increased b values. At low b
values (< 200 s/mm2), there is a deviation from the
mono-exponential decay, which is due to incoherent
motions of water molecules inside the microvascula-
ture (Fig. 4) [35, 36]. On its part, DKI model analyzes
the deviation of tissue diffusion from a Gaussian pat-
tern at ultra-high b values (typically > 1000 s/mm2)
[37]. SEM evaluates the effects of sub-voxel hetero-
geneity in diffusion. Finally, VERDICT couples DWI to). Diffusion signal evaluated using different models of analysis:
(b), diffusion kurtosis imaging (DKI) (c), and diffusion tensor
e model of analysis, including ADC, perfusion fraction (f), or
l and physiological correlation of parameters obtained from
or type
Fig. 4 Rectal cancer in a 65-year-old woman. a Axial T2-weighted image demonstrated a rectal mass deeply extending to the mesorectal fat
(white arrow). b Perfusion fraction (f), apparent kurtosis diffusion (Kapp), and the curve of signal intensity decay in diffusion pretherapy. Note that
this curve showed a marked attenuation of signal intensity at low b values (red arrow) due to the influence of tumor perfusion on diffusion. c
Following therapy, there are reduction of both f and Kapp and dissapearance of the fast attenuation of the signal intensity at low b values,
related to tumor response with reducer perfusion on IVIM model
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it may allow the assessment of tumor features such as
cell size, vascular volume fraction, and intra- and
extracellular volume fractions [24, 25].Biological bases of DWI
Diffusion measures the random (Brownian) motion of
water molecules at microscopic level. However, diffusion
is not free in tissues and is modified by interactions
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branes, and macromolecules and by macroscopic
water movements (e.g., within blood vessels and glan-
dular ducts). The use of DWI in tumor evaluation is
based on the assumption that malignant tumors are usu-
ally more cellular and have a more complex
extravascular-extracellular space than benign tumors/nor-
mal tissues, causing a lower attenuation of the signal in
tumors with increased b values [21, 28–31]. As a general
rule, water diffusion decrease with the increased cellularity
and cell size (24b). Negative correlations between the
ADC values and cellularity or proliferation have been
reported in many tumor types; though, there were no clear
correlations in others [32, 33]. It must be also considered
that molecular mobility is anisotropic, not equal for all
directions. Based on this, diffusion tensor imaging (DTI)
may describe the magnitude, degree, and orientation of
diffusion anisotropy and may estimate the tissular micro-
structure. Characterizing the non-Gaussian diffusion MRI
signal behavior may also provide valuable information on
tissue structure and function. IVIM model allows the sep-
aration of pure diffusion characteristics from pseudodiffu-
sion and perfusion features. IVIM-derived parameters
include the pure molecular diffusion coefficient (D), theFig. 5 A 68-year-old man with lung adenocarcinoma. a The whole-body d
deposit in the sacrum (white arrow). b Coronal reformatted T1W images ob
(FAT) (middle), and fat-fraction in colored scale (right) evidenced not fat coperfusion-related diffusion coefficient (D*), the perfusion
fraction (f), and the relative perfusion (fD*) (Fig. 4). The
biological meaning of these parameters is not entirely
clear. However, the f values have been suggested to be
related to the blood volume (BV) and have been signifi-
cantly correlated with the percentage of arterial enhance-
ment in different tumor types [34–36]. On its part, D* and
fD* may hold information on blood speed and on the
quantity of blood flowing through a unit tissue per unit
time, respectively [34]. Most studies have also found a fair
to good correlation between f and histological surrogate
markers of angiogenesis, such as the microvessel density
(MVD), and parameters derived from perfusion imaging
techniques [34–36]. DKI provides an additional model of
diffusion analysis at higher b values (> 1000 s/mm2), in
which the signal contribution of water from the extra-
cellular space is substantially reduced, making the dif-
fusion measurement more sensitive to the motion of
water in the intracellular compartment. However, in
the case of DKI- and SEM-derived metrics (e.g., ap-
parent kurtosis [Kapp] or the stretching parameter
[α]), these parameters do not have a simple biological
interpretation; although presumably may reflect tissular
heterogeneity (Fig. 4) [37].iffusion weighted MR image (b = 900 s/mm2) depicted a metastatic
tained using the Dixon technique water only (WATER) (left), fat only
ntent and increased water in the metastatic lesion (white arrow)
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– Qualitative evaluation
The diffusion signal alterations serve as an excellent
qualitative tool, providing an additional contrast me-
chanism to supplement routine conventional sequences.
Areas retaining high SI on high b values images suggest
highly cellular tissues, such as tumors [28–31] (Fig. 5).
This feature may be a useful clinical tool. A recent
meta-analysis reported that visual assessment of tumor
diffusion might be more accurate than ROI measure-
ments of ADC for PCa detection [38]. However, high
signal intensities on DWI are not always reliable indica-
tors of increased cellularity, and high b values images,
ADC maps, and co-registered anatomical images should
always be evaluated together (Table 1).
– Quantitative evaluation
The ADC has served as a quantitative biomarker for the
evaluation of diffusion in clinical practice. Calculation of
an ADC value is typically performed utilizing a mono-
exponential fit of the diffusion signal at different b values.
There is a linear decay of the natural logarithmic diffusion
SI as the b value is increased. The slope of this line is theTable 1 Interpretation of tumor diffusion-weighted images
Signal intensity
on high b-value
images (b800–
b1000)
Relative value on
apparent diffusion
coefficient (ADC)
maps
Signal
intensity on
T2-weighted
images
Interpretation
High Low Intermediate Generally, high
cellularity tumor
Coagulative
necrosis
Abscess
Rarely high
protein content
High High High T2-shine through
(often
proteinaceous
fluid)
Low Low Low Fibrous tissue
with low water
content +/-
viable tumor
Low High High Fluid
Liquefactive
necrosis
Lower cellularity/
grade tumor
Glandular tissue
Low High High Vasogenic edema
(T2-wash out)
Low Low Variable Hemorrhagic
content (T2-black
out)ADC value (units 10−3 mm2/s). Malignant lesions usually
have lower ADC values compared to surrounding normal
tissue, edema, and benign tumors [28–31]. Unfortunately,
there is considerable disparity in the published ADC
values across different anatomies, vendors, or technical
parameters of the acquisition causing that there are no
unique cut-off ADC values that distinguish cancer from
normal tissues. Besides, both well-differentiated tumors
and necrotic poorly differentiated tumors may show high
ADC values and some normal tissues (including endome-
trium, bowel mucosa, testes, and normal LNs and nerves)
may show increased SI on high b value [28–31]. Finally,
non-Gaussian models yield several quantitative parame-
ters that may improve diffusion assessment. Malignant
lesions usually present high values of f and Kapp and lower
values of α [27, 34, 37].
Clinical value
DWI has shown clinical value for tumor detection, diag-
nosis and grading, staging, prognosis, therapy monitor-
ing, detection of tumor relapsing, and assessment of
patient’s outcome [27, 31, 34, 39–44]. Malignant tumors
are generally more cellular than benign tissues and show
lower ADC values. However, false positive results may
occur with abscesses and infective processes and false
negatives may happen with cystic, necrotic lesions and
in well-differentiated neoplasms (particularly adenocar-
cinomas) [27–30]. DWI has also demonstrated to be an
effective tool for evaluating tumor response to therapies
[40–44]. Successful treatment is usually reflected by in-
creases in ADC values. However, it depends on the
mechanism of action of therapy given. Transient de-
creases in ADC can also be observed in patients treated
with anti-VEGF therapies in brain tumors [43, 44]. This
finding appears to be related to cellular swelling and re-
ductions in tumor BF, extracellular space, and vasogenic
edema. Accurate imaging response evaluations of onco-
logic patients are sometimes notoriously difficult with
conventional imaging techniques, especially in the case of
bone lesions. In this setting, whole-body (WB)-DWI MRI
has shown clinical value for the assessment of therapeutic
response in patients with metastatic bone disease, multiple
myeloma, and lymphoma [41, 43–54] (Figs. 6 and 7).
Finally, regarding the prognostic/predictive value of ADC
in tumor assessment, lower ADC values are usually asso-
ciated to patients with poor outcome; although are corre-
lated to a favorable response to most treatment options.
IVIM represents an alternative to perfusion contrast-
enhanced techniques without the use of contrast agents
in oncologic imaging. IVIM-metrics (mainly f ) have
demonstrated to be useful for tumor diagnosis and
characterization in liver, pancreatic, breast, H&N, brain,
renal, cervical, and rectal tumors [35, 55]. IVIM has also
shown promising results for monitoring therapy response
Fig. 6 A 52-year-old woman with metastatic breast cancer treated with chemotherapy (a). Whole body diffusion-weighted inverted gray-scale
maximun intensity projection (MIP) of b = 900 s/mm2 images superimposing the ADC values associated with each voxel in color scale before (left)
and after one cycle of therapy (right). Red colored voxels represent untreated disease or those with no-detectable response. Thus, yellow voxels
represent regions “likely” to be responding. Green colored voxels have ADC values ≥ 1500 μm2/s representing voxels that are “highly likely” to be
responding with tumor cell kill. Tumor evaluation showed a great change in ADC values (predominantly green voxels with ADC values ≥ 1500 μm2/s)
indicating tumor necrosis. b A detailed ADC analysis of histogram metrics evidenced a reduced tumor volume as well as improvement in several
histogram metrics (mean ADC, kurtosis, etc.) that have changed significantly during treatment due to extensive necrosis (compare to Fig. 7)
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agents) in clinical practice [21, 35, 55].
Clinical applications of kurtosis have been mainly fo-
cused on prostate, breast, H&N, lung, renal, and brain
tumors. Published data suggests that DKI may provide
additional information and may improve tumor diagno-
sis and characterization compared with conventional dif-
fusion parameters in these tumor types [37]. Up to now,
SEM has been used in a limited way in the evaluation oftumors. Preliminary data of the use of this technique
have been published in prostate, breast, cervical, rectal,
ovarian, and H&N cancers and gliomas [37].
Tissular composition and imaging
Imaging (specially MRI) may allow the depiction of
tumor composition. Several tumor types show character-
istic imaging findings. For instance, melanin (a paramag-
netic substance) shortens the T1 relaxation time, making
Fig. 7 A 63-year-old woman with metastatic breast cancer treated with an anti-HER2 agent and hormonotherapy. a Whole body diffusion-
weighted inverted gray-scale maximun intensity projection (MIP) of b = 900 s/mm2 images superimposing the ADC values associated with each
voxel in color scale before (left) and after one cycle of therapy (right). Red colored voxels represent untreated disease or those with no-detectable
response. The yellow voxels lie between the 95th centile value of the pre-treatment histogram and 1500 μm2/s. Thus, yellow voxels represent
regions “likely” to be responding. Green colored voxels have ADC values ≥ 1500 μm2/s representing voxels that are “highly likely” to be
responding with tumor cell kill. In this case, response assessment demonstrated a discrete change in ADC values (predominantly yellow voxels). b
The detailed ADC analysis of histogram metrics evidenced an increased tumor volume with moderate changes in several histogram metrics
(mean ADC, kurtosis, etc.) suggesting an apoptotic effect of targeted therapies (compare to Fig. 6)
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MRI is a useful tool for the assessment of fat content,
T1, T2, or T2* mapping, or MT. MRI fat quantification al-
lows monitoring bone marrow (BM) composition in onco-
logic patients and BM changes that result from therapy.
BM has variable composition and vascularization (Fig. 5).
Yellow BM is primarily composed of fat (> 80%), while rednormal red BM or bone tumor infiltration usually show
and increased percentage of water (30–40% water in nor-
mal red BM). These features may be useful in the evalu-
ation of patients with metastatic bone disease for diagnosis
or therapy response assessment [43, 50, 53, 56–58].
Besides, each biological tissue has a T1 and T2, or T2*
relaxation times based on its cellular and interstitial
Fig. 8 (See legend on next page.)
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Fig. 8 An 8-year-old patient with high-grade tectal plate glioma (white arrow). a Post-contrast T1-weighted (+C) and magnetization transfer (MT)
images were obtained before (top row) and after (bottom row) chemoradiotherapy; and (b) the corresponding MT ratio histograms of lesion are
as shown. The magnetization transfer acquisition comprised a set of four geometry-matched 3D-GRE scans: two flip angles (4 and 24°), with/
without MT pulse (1.5 kHz offset) on a 1.5 T MR system. Note the reduction in the MT ratio (histogram in b) associated with response to
treatment, accompanied by slight increase in size and enhancement of the tumor (a). [Images courtesy of Dr. Neil P. Jerome, Norwegian
University of Science and Technology]
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characteristics such as excess of water (e.g., edema), pro-
tein deposition, and the presence of other T1-altering sub-
stances, such as lipid or iron (hemorrhage, siderosis).
Quantitative T1 mapping requires a series of images using
different inversion times to derive a T1 recovery curve
resulting in a map that describes the relaxation value on a
pixel-by-pixel basis, expressed in milliseconds. In oncol-
ogy, studies about the use of T1 values in tumors
evidenced that this parameter was greater than in normal
tissues due to an increased extracellular space. On the
contrary, low tumor T1 values have been correlated to in-
creased necrosis, low water content, and high levels of
proteins [59]. Native T1 mapping could also represent an
in vivo biomarker for the differentiation of tumor grade
[60]. Significant changes in T1 were shown in several
pre-clinical models in response to therapy [59, 61]. The
use of T2 mapping in oncology has been mainly focused
on PCa. Sabouri et al. have demonstrated the feasibility of
T2-derived parameters (e.g., luminal water fraction) in the
detection and grading of cancer [62]. T2 values were sig-
nificantly lower in Gleason ≥ 7 than in Gleason ≤ 6 cancers
in peripheral zone, but this parameter will not be sufficient
by itself to adequately characterize focal abnormalities. An
explanation of this feature may be the effect of normal
prostate tissue interdigitated with malignant glands, which
may reduce contrast between tumor and normal prostatic
tissue [63]. Finally, quantitative T2* mapping seems also to
be a method that may be potentially useful for characteriz-
ing malignant tumors. In this setting, T2* mapping showed
greater diagnostic accuracy than ADC mapping in the
characterization of intermediate- and high-grade PCa, al-
though it also demonstrated a limited value in the
characterization of low-grade PCa [64]. In the case of
breast cancer, the T2* value is significantly longer in inva-
sive cancers compared with ductal carcinoma in situ and
in high-grade tumors [65]. Unfortunately, a reliable diag-
nosis of malignancy cannot be made on the basis of a
quantitative evaluation of T1, T2, or proton density
indexes.
MT imaging and chemical exchange saturation transfer
(CEST) can evaluate the presence of molecules other than
water. MT may be useful for evaluating tissues with sig-
nificant water-macromolecule interactions. This technique
has showed promising results as a possible tool for tumor
assessment in prostate, testicle, rectal, breast, and braintumors (Fig. 8) [66]. On its part, CEST is just one type of
MT. CEST can detect low concentrations of molecules
through the presence of 1H protons that are exchange-
able with those of water causing a decrease of signal
intensity. Amide proton transfer (APT) imaging is the
most widely used CEST technique. APT imaging for
cancer assessment has been mainly focused on the brain,
but higher APT values have been found in malignant
tumors compared with those in normal tissues and benign
lesions in brain, breast, prostate, chest, and H&N. APT
values also varied between malignant groups and tumor
grades [67, 68].
Spectral CT also enables material identification (cal-
cium, fat, etc.) and quantification, providing increased
tumor detection and characterization [69]. In this setting,
for example, Kosmala et al. reported that material-specific
image processing may facilitate the identification of BM
tumor infiltration [70].
Tumor microenvironment
The biology of tumors can no longer be understood sim-
ply by evaluating tumor cells but instead must include
the contributions of the tumor microenvironment
(TME) to tumorigenesis. TME is a complex, heteroge-
neous, and dominant component of solid tumors. TME
includes the acellular component (named the extracellu-
lar matrix, ECM) and different co-opted cell types, in-
cluding cancer-associated fibroblasts, mesenchymal cells,
and immune infiltrate. The non-malignant cells of the
TME can comprise > 50% of the mass of tumor burden.
TME plays critical roles in both promoting the malig-
nant progression of solid tumors and modifying the re-
sponse of solid tumor cells to therapy. Pathological TME
usually shows insufficient oxygenation (hypoxia) and acid-
osis. Multiple imaging modalities have been employed to
evaluate the TME, but most of them are still at the
pre-clinical phase of testing [71–73].
Imaging of tumor stroma
Apart of the study of tumor vascularization, imaging
evaluation of tumor stroma has been scarce. The stroma
can make up a significant proportion of a tumor volume,
and differs from normal stroma, showing a high number
of fibroblasts, deposition of type I collagen and fibrin,
and a marked infiltration of inflammatory cells. Stroma
may deeply influence imaging findings of tumors (Fig. 9).
Fig. 9 Desmoplastic reaction in a 51-year-old patient with pancreatic adenocarcinoma. a Imaging evaluation including an axial fat-suppresed
contrast-enhanced T1-weighted dynamic MR image (DCE-MRI, top, left), a time/signal intensity curve analysis (botton, left), a parametric map
corresponding to the initial area under the curve (iAUC), and a fusion of axial T2-weighted image fused with a superimposed color-coded map
derived from high b value DWI (FUSION) clearly showed a hypoperfunded mass with a pattern of progressive enhancement (curve type 1, red
arrows) and no restricted diffusion in the tumor in the fusion image. These findings were secondary to the predominance of fibrosis within the
lesion. b Histological analysis (H&E, × 20) confirmed an abundant tumor desmoplastic reaction (asterisks) with clusters of tumor cells (arrow)
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plastic cells may only represent as little as 10% of
tumor volume in pancreatic adenocarcinoma, associ-
ated to the presence of abundant desmoplastic
stroma. Although these tumors usually showincreased angiogenesis on histological analysis,
tumor imaging findings are deeply modified by stro-
mal fibrosis, a feature which explains that pancreatic
adenocarcinomas usually show a diminished en-
hancement in the early phase of dynamic
Fig. 10 BOLD sequence and tumor oxygenation. a Axial T2-weighted image in a 63-year-old man evidenced a poor defined hypointense mass in
the anterior part of the transitional gland corresponding to prostate cancer (white arrow). b BOLD exam acquired in the axial plane at baseline
and after evidenced that in baseline conditions the tumor (white arrow) showed low signal in the T2* map (high R2* values), which is related to
a lower oxygenation compared to the rest of the prostate. BOLD images after 95% oxygen breathing at 5, 10, and 15 m evidenced that the
signal increased witihin the tumor (red arrow in the acquisition at 15 min) with an inverted ΔR2* time-intensity curve (red arrowhead). These
features evidence the presence of radiosensitive areas within the tumor with increasing pass of oxygen from blood to the tissue. The
concentration of deoxyHb increases with rising oxygen consumption, leading to a decreasing T2* relaxation time of the surrounding tissue
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enhancement in the late phase (Fig. 9).Imaging of tumor-infiltrating immune cells
Interactions between tumor cells and immune cells are in-
volved on the initiation, progression, therapy-resistance,
and prognosis of cancer. Besides, immunotherapy has
successfully been introduced in the clinic for many cancer
types (especially in cancer types with high mutation rates).
To date, there is a limited experience with the evaluation
of tumor-infiltrating immune cells and responses to
immunotherapy in clinical practice and there is a lack of
imaging tools to measure the behavior of immune cell
populations, which is hampering the optimization and
individualization of immunotherapy [74].Imaging of oxygenation and hypoxia in cancer
Tumor hypoxia leads to treatment resistance, enhanced
tumor progression, and has a negative impact on patient
prognosis and survival in cancer. Hypoxia changes the
pattern of gene expression resulting in a more aggressive
tumor phenotype [75]. Oxygen-enhanced MRI, including
blood oxygenation level dependent (BOLD) and tissue
oxygen level dependent (TOLD) techniques, and PET
imaging based on mitroimidazole analogues and com-
plexes of copper with diacetyl-bis(N4-methylthiosemi-
carbazone) (ATSM) provide a noninvasive assessing of
tumor oxygenation [75–77].Biological bases of tumor hypoxia
Uncontrolled cell proliferation and the inability to form
normal blood vessels results in impaired blood supply
and low oxygen tension within tumors. Hypoxia acti-
vates adaptive cellular responses and genomic instability
that contribute to tumor progression and is associated
with poor prognosis and resistance to different therapies,
potentially contributing to poor patient survival. Two
main types of tumor hypoxia are recognized [76, 77]: (1)
acute (perfusion-related) hypoxia resulting from inad-
equate BF in tumors due to structural and functional ab-
normalities of tumor vasculature and (2) chronic
hypoxia, which is the most relevant type in oncology.
Two fundamental mechanisms of chronic hypoxia can
be differentiated: diffusion-limited hypoxia (caused by
increased oxygen diffusion distances due to tumor
growth) and hypoxia due to a compromised perfusion
due to inefficient and leaky microvessels.Technical features
– Oxygen-enhanced MRIBOLD-MRI contrast derives from variations in the
magnetic susceptibility of blood due to changes in the
concentration of deoxyhemoglobin. Deoxyhemoglobin
increases the transverse relaxation rate (R2*) of water in
blood and surrounding tissues. This change in magnetic
susceptibility produces local magnetic fields around
blood vessels, changing signal intensity on MR images
(Fig. 10). BOLD provides an indication of tumor blood
oxygenation, but is also sensitive to vessel density, blood
flow hematocrit, and pH [77]. On its part, TOLD MRI is
based on T1-weighted contrast and the measured R1
(=1/T1) is also sensitive to tissue oxygenation.
– Radiotracers
18F-fluoromisonidazole (18F-FMISO) is the main
mitroimidazole analogue and constitutes the most exten-
sively clinically studied PET hypoxia biomarker. FMISO
enters cells under hypoxic conditions and becomes
trapped at rates that are inversely proportional to the
local pO2.
18F-FAZA is another PET imaging tracer of
tumor hypoxia that offers the advantage of higher
tumor-to-reference tissue ratios in comparison with
18F-FMISO.
Combinations of cooper with ATSM ligands, such as
64Cu-ATSM, also appear to be promising radiotracers
for delineating the extent of hypoxia within tumors with
PET. Under hypoxic conditions, the unstable cooper-
ATSM complex may dissociate, causing its intracellular
trapping [78].Clinical value
BOLD images do not measure tissue pO2 directly and
are more likely to reflect acute than chronic tissue hyp-
oxia. Moreover, it is necessary to know the distribution
of blood volume (BV) in tissue in order to be able to
correctly interpret R2* images, thereby permitting infer-
ence of oxygenation status. However, a significant link
was found between R2* and pimonidazole histology (a
marker of hypoxia) in patients with PCa [79]. The re-
sults showed that the sensitivity of R2* in depicting
tumor hypoxia was high (88%), but its specificity was
low (36%). Concerning the role of oxygen-enhanced
MRI in clinical practice, several published studies have
shown a value for assessing tumor oxygenation and pre-
dict radiation response [80].
On its part, PET imaging of hypoxia has demon-
strated clinical value in many different tumor types
facilitating the identification of hypoxic tumor areas,
predicting prognosis and response to treatment, im-
proving radiotherapy planning, and allowing the develop-
ment of hypoxia therapeutics by measuring response to
hypoxia-modifying treatments.
Fig. 11 Theranostic in oncology with PSMA. 177Lu-PSMA radioligand therapy in a 67-year-old man with metastatic castration-resistant prostate
cancer. a Pretherapy. PET image evidenced a difuse metastatic involvement. PSA value 50 ng/ml. b 4 months following the treatment with
177Lu-PSMA radioligand therapy (8000 MBq), PET showed a complete metabolic response. PSA value 0 ng/ml
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Glycolytic metabolism and the hypoxic microenviron-
ment lead to extracellular acidosis in solid tumors.
Major approaches for pH imaging include MRS, MT
methods, and pH-dependent relaxation agents, although
with a limited clinical use [81]. Published preclinical data
have evidenced the presence of an acidic extracellular
pH and alkaline intracellular pH in tumors relative to
normal tissues [76, 82, 83].
Imaging the expression of specific molecular
characteristics
Tumor cells may overexpress some specific receptors,
antigens, and proteins. Specific markers such as the
prostate-specific membrane antigen (PSMA) (Fig. 11),
the epidermal growth factor receptors (EGFR), the
human epidermal growth factor receptor-2 (HER-2),the androgen receptor, the somatostatin receptors
(SSTR), the C-X-C motif chemokine receptor 4
(CXCR4), and bombesin receptors represent excellent
examples of targets for cancer imaging and therapy in
different tumor types [84] (Table 2).
Clinical value
An important characteristic of neuroendocrine tumors
(NETs) is the expression of SSTR on their cell mem-
branes [85]. The SSTR2, SSTR3, and SSTR5 SSTR sub-
types are often overexpressed on NETs in almost 90% of
cases. The determination of the status of somatostatin
receptor expression is needed to select patients for pep-
tide receptor radionuclide therapy. For a long time,
111In-octreotide (Octreoscan) has been considered the
reference for imaging NETs. However, at present,
68Ga-DOTA-somatostatin analogues represent the “new
Table 2 Radiotracers in the evaluation of tumor characteristics
Radiotracer Biological Correlation Tumor Type Main indications
FDG Energetic glycolytic metabolism Many tumor types Diagnosis, staging, response,
prognostic value, relapsing tumor
Choline radiotracers Cellular membrane turnover and
phosphatidylcholine metabolism
Prostate
Bladder, Brain
Diagnosis, staging, relapsing tumor
Methionine Amino acid transport and protein
synthesis
Brain and head and neck Diagnosis, grading, response,
prognostic value, relapsing tumor
Acetate Lipid synthesis and energetic
metabolism
Prostate
Hepatocellular carcinoma
Diagnosis, staging, relapsing tumor
DOPA Dopamine uptake and metabolism Neuroendocrine tumors Diagnosis, staging, relapsing tumor
FLT Cellular proliferation and tyrosine
kinases-1 activity
Lung, Lymphoma,
Colorectal. Gastric and
Pancreas
Diagnosis and tumor response
Sigma-2 (σ2) Receptor σ2 receptors are expressed in
proliferating tumor cells
Diagnosis and treatment evaluation
Integrin targeted Imaging agents (RGD)
and VEGFR targeted Imaging agents
Angiogenesis Preclinical use
Annexin V Tumor Apoptosis Preclinical use
Nitroimidazoles (FAZA, FMISO)
Cu-ATSM
Tumor hypoxia Preclinical use
Radiotracers Specific Tumor Types
Radiotracers Targeting Specific Tumor
Markers
EGFR expression
PSMA expression
Chemokine receptor type 4 (CXCR4)
DOTA-peptides (Somatostatin
receptors)
Bombesin receptors
Lung, Colorectal
Prostate
Breast and head and neck
cancer metastasis
Neuroendocrine tumors
Prostate, breast, small cell
lung cancer, GIST
Preclinical use
Relapsing tumor. Staging and
tumor response
Preclinical use
Diagnosis, staging, relapsing tumor,
response assessment
Non-Tumoral metabolic pathways
NaF Bone metabolism (non-specific
tumor tracer)
Bone metastases Diagnosis and staging
64CuATSM diacetyl-bis(N4-methylthiosemi-carbazone) copper(II)), EGFR epidermal growth factor receptor, FAZA fluoroazomycin arabinoside, FDG
fluorodeoxyglucose, FLT fluorothymidine, FMISO fluoromisonidazole, GIST gastrointestinal stromal tumors, NaF sodium fluoride, PSMA prostate-specific membrane
antigen, VEGFR vascular endothelial growth factor receptor
García-Figueiras et al. Insights into Imaging           (2019) 10:28 Page 17 of 35gold standard” for imaging NETs, offering high sensitiv-
ity and specificity and providing important diagnostic,
therapeutic, and prognostic data. On its part, EGFR
overexpression has been shown to correlate with aggres-
siveness of tumors and poor survival of patients in many
tumor types. Imaging evaluation of EGFR expression
(e.g., cetuximab DOTA-labeled PET imaging) may facilitate
patient selection for HER therapy and monitor treatment
response [86]. The PSMA is highly expressed on most PCa,
although 5–10% of primary PCa or PCa metastatic deposits
have negative PSMA results on PET. PSMA expression is
usually increased in advanced stages, including metastatic
castrate-resistant PCa. Unfortunately, high PSMA expres-
sion has also been described in other tumor types (colon,
kidney, breast, and bladder cancer), in benign lesions (e.g.,
schwannomas, thyroid adenomas), and normal tissues,
which may cause potential imaging pitfalls [87].
PSMA-based PET imaging may have considerable in-
fluence on the management of primary (intermediate-and high-risk) PCa patients as well as early recurrent
disease [88]. Besides, PSMA may also represent a pos-
sible target for therapy in advanced PCa (Fig. 11). Fi-
nally, CXCR4 plays a pivotal role in tumor
development and metastasis and it is overexpressed in
many solid and hematologic cancers. The CXCR4 re-
ceptor also represents a promising target for imaging
and radionuclide therapy [89].Imaging main tumor hallmarks
The hallmarks of cancer (biological characteristics
acquired during the initiation and progression of tu-
mors) represent key features of tumors. Imaging tech-
niques have unique potential to comprehend most of
these tumor-related characteristics, including metabolic
reprogramming, sustaining proliferative signaling and
evading growth suppressors, resisting cell death and
apoptosis, and inducing angiogenesis [1, 2].
Fig. 12 An axial 18F-Choline PET/CT image depicted a mass in the
prostate bed (white arrow) in a 72-year-old man with a biochemical
relapse of a prostate cancer following radical prostatectomy
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Changes in cell metabolism can contribute to malignant
transformation and tumor progression. Tumor meta-
bolic phenotypes influence tumor prognosis and treat-
ment and can be exploited to image tumors [90].
Metabolic alterations in cancer cells include the
increased generation of energy and biosynthetic interme-
diates needed for cell growth and proliferation. Molecu-
lar imaging techniques, which include MRSI, PET, and
SPECT imaging, can assess the altered metabolic profiles
of tumors [91].
Molecular imaging with radiotracers
Over the last decade, many promising tumor-specific ra-
diotracers have been developed and evaluated for asses-
sing tumor metabolic changes with PET and SPECT [84,
92, 93] (Table 2).
Biological bases of metabolic imaging with radiotracers
– Energetic metabolism (glycolysis)
Reprogramming of the energetic metabolism is a fun-
damental characteristic of cancer. The first discovered
metabolic phenotype was aerobic glycolysis (Warburg
effect), by which energy generation shifts from oxidative
phosphorylation to anaerobic glycolysis, even under nor-
mal oxygen concentrations [92]. 2-[18F]-fluoro-2-deoxy-D--
glucose (FDG) is the radiopharmaceutical most frequently
used for clinical PET imaging. FDG is a glucose analog that
can be transported into cytoplasm by glucose transporters
(Glut). Malignant tumors have a higher metabolic rate
and generally express higher numbers of membrane
Glut than normal cells. This results in increased up-
take of FDG by tumor cells and forms the basis of
FDG-PET imaging. In general, higher-grade and
less-differentiated tumors are associated with higher
uptake of FDG [84, 94–97].
– Biosynthetic metabolism
Malignant transformation is also associated with an
abnormal anabolic metabolism due to the increasing
growing rate. New radiopharmaceuticals have been
developed that are capable of giving more specific
tumor information of the changes in tumor biosyn-
thetic metabolism, including increased cellular mem-
brane turnover (Choline [Cho]-PET), altered amino
acid and protein synthesis (methionine-PET), in-
creased nucleotide (fluorothymidine [FLT]-PET), and
lipid (acetate-PET) synthesis [84, 95] (Fig. 12). Be-
sides, molecular imaging allows the evaluation of
tumor-specific metabolic pathways, such as dopamine
uptake and metabolism in NETs. All this metabolic
information may lead to a better sensitivity and speci-
ficity in tumor assessment.Technical features
PET imaging is based on the injection of a radiotracer
containing a positron emitter. Positrons annihilate with an
electron within milliseconds of its emission, releasing two
photons moving in opposite directions, which are detected
during PET creating a digital image that represents the
distribution of the radiotracer in the body. In the case of
SPECT, the patient is injected with a radiopharmaceutical
and emits radiation in the form of gamma rays, which are
detected by a gamma camera. The combinations of a dedi-
cated PET scanner and multidetector CT (PET/CT) or
MRI (PET/MRI) have enabled integrated molecular,
functional, and high-resolution morphologic imaging
and currently play a critical role in oncology. PET/CT
or PET/MRI data result in higher sensitivity and speci-
ficity of cancer assessment compared to PET alone.
Combined PET/MRI brings the inherent advantages of
MRI, including lack of ionizing radiation exposure,
increased soft tissue contrast, and the possibility of a
multiparametric imaging based on the combination of
MR-based imaging techniques.
Interpretation guidelines
Visual interpretation of radiotracer uptake is the basis of
the clinical report in PET/SPECT imaging. Absolute
quantification would require complex dynamic protocols
and repeated measurement of activity concentrations in
arterial blood. Thus, normalization approaches have
been included in clinical practice. Normalization is
based on the measured radiotracer concentration with
regard to the injected activity per weight, which re-
sults in a semiquantitative index, called standardized
uptake value (SUV) (Fig. 13). Qualitative scales have
been also used in clinical practice. Lesion uptake is
compared with the uptake of a reference tissue uptake
(e.g., mediastinum or liver), such in the Deauville
five-point scale of lymphomas [96].
Fig. 13 Liver metastasis of a gastrointestinal stromal tumor (GIST) in a 68-year-old man. T1-weighted contrast-enhanced MRI (DCE) images and
FDG-PET SUV parametric maps (SUV) acquired pretherapy (a) and following the administration of imatinib (b) and pretherapy (a), imaging
findings evidenced a metabolic active tumor with areas of heterogenic enhancement (white arrows). Post-therapy (b), the tumor presented
almost a total absence of enhancement and a complete metabolic response on PET imaging
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SPECT and PET have been used for the evaluation of
molecular processes in cancer patients. SPECT techno-
logy had greater accessibility, lower cost, and availability
of a wider range of approved radiotracers. However, PET
currently has substituted many existing SPECT onco-
logic applications due to its superior resolution, speed,
and quantitative capability [98, 99].
– FDG-PET imaging
FDG is currently the most used radiotracer in clinical
practice. A review of the literature established an average
FDG-PET sensitivity of 84% and specificity of 88% across
all oncology applications [100]. Besides, reported fre-
quencies of change of patients’ management based on
PET findings ranged from 30 to 40% in the literature. PET
was associated commonly with the demonstration of
greater cancer burden or more anatomic sites involved
[101, 102] and the metabolic tumor volume, which com-
bines the dual characteristics of three-dimensional volu-
metric data and the metabolic activity of tumor based on
FDG uptake, has been shown to be a predictor of patient
outcome in human solid tumors [103]. Main clinical indi-
cations of FDG-PET/CT in oncology include (a) biopsy
guidance, (b) evaluating the extent of disease in knownmalignancies (staging/restaging), (c) therapy planning, (d)
predicting pre- and intra-treatment cancer treatment out-
comes, (e) establishing tumor prognosis, (f) evaluating
tumor response to therapy (Fig. 13), and (g) follow-up to
detect cancer recurrence (especially in asymptomatic
patients with rising tumor marker levels and those with
negative or equivocal conventional imaging findings)
[100–102]. Although PET/CT is not frequently used in
the setting of tumor diagnosis, differentiating benign
from malignant lesions (e.g., in the case of single pul-
monary nodules) and searching for an unknown pri-
mary are also recognized clinical uses of FDG-PET
imaging.
New technologies such as dedicated PET imaging devices
and PET/MRI technology have been developed to improve
cancer imaging. Dedicated PET has been mainly used in
breast cancer and brain imaging. Mammography with mo-
lecular imaging PET (MAMMI-PET) is a system for
dedicated hanging-breast imaging without compression.
MAMMI-PET offers higher sensitivity for primary breast
cancer lesions comparing to conventional PET/CT [104]
(Fig. 14). On its part, PET/MRI technology is being used in
those clinical scenarios in which sequential PET and MRI
are the standard of care, particularly in brain, liver, bone, or
pelvic imaging, but also in children or in those patients
undergoing repeated imaging for whom cumulative
Fig. 14 A 48-year-old woman with breast cancer. a Axial contrast-enhanced T1-weighted MR image of breasts performed during last week of
menstrual cycle showed bilateral multiple nodular areas of enhancement in both mammary glands (white and red arrows). b A dedicated FDG-
PET exam only depicted a nodular mass (red arrow) with increased FDG uptake in the right breast, corresponding to a invasive ductal carcinoma
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able and in whole-body staging. However, robust stud-
ies demonstrating utility in clinical practice are
needed [105–107].
Finally, it is necessary to consider that the value of
FDG-imaging in oncology depends on several factors,
such as the specific tumor type or the anatomic are of
interested. FDG-PET presents recognized limitations, in-
cluding (a) low sensitivity in well-differentiated/low--
grade cancers, tumors with relatively low glucose
metabolism (e.g., non-FDG-avid lymphomas, RCC, and
bronchoalveolar cell carcinoma), hypocellular cancers
(such as mucinous tumors), and tumors with low
expression of Glut-1 such as PCa; (b) false positive up-
take in benign processes (infection and inflammatory le-
sions); and (c) increased FDG accumulation in some
normal tissues (brown fat) and metabolically active or-
gans (e.g., heart and brain) [91, 99–102].
– Non-FDG PET imaging
Apart of FDG-PET imaging, various other new
tracers are gaining a remarkable place in clinical
practice for cancer imaging [84, 94]. Malignant
transformation is associated with an abnormal Cho
(an essential component of phospholipids and cellmembranes) metabolism based on both the increas-
ing growing rate and on the upregulation of Cho
kinase. The use Cho labeled with 11C or 18F is
mainly focused on the restaging of patients with bio-
chemical failure of PCa. However, the detection rate
of Cho-PET varies depending on the site of recur-
rence, prostate-specific antigen levels, and the
presence of hypoxia (which decrease the uptake of
Cho-labeled radiotracers). On the other side,
11C-methionine may reflect amino acid transport and
protein metabolism. This tracer has a main advantage in
brain tumor imaging compared with FDG, because there is
almost no tracer uptake in normal brain tissue (Fig. 15).
11C-acetate is an indirect biomarker of fatty acid synthesis,
which is also upregulated in several tumors. In clinical prac-
tice, acetate-PET has a major application in imaging tumors
in which FDG-PET is of limited use, such as PCa, renal
cancer, and hepatocellular carcinoma. Finally, NETs have
distinctive biochemical features based on an increased
dopamine metabolism, which allow the possibility to image
and treat these tumors with specific radioligands [85].
MR spectroscopy
MRS and MRSI enable in vivo measurements of a
complete spectrum of metabolites that are present at
millimolar concentration.
Fig. 15 Relapsing brain astrocitoma (white arrow) in a 54 year-old-man.
a 18F-FDG and b 11C-methionine coronal-reformatted images. Normal
uptake of FDG in brain impeded an adequate tumor detection and
delineation. However, 11C-methionine PET clearly depicted the tumor
(white arrow)
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MRS/MRSI
Cancers usually display altered peaks of different
biological-meaning metabolites, including Cho, creatine
(Cr), lactate (Lac), lipids (Lip), citrate (Ci), etc. The
diagnostic importance of a metabolite is depending on
the type of tumor and on the organ/anatomical area to
be studied [108, 109] (Table 3).
Technical features
Spectroscopy uses the free induction decay (FID) follow-
ing a radiofrequency to obtain metabolite information.
One-dimensional Fourier transforms of the FID gives
spectra with peaks, whose areas are proportional to the
abundance of metabolites. MRS provides information
about the chemical environment of the nuclear spin,
which depends on the neighboring nuclei and overall
chemical structure. This chemical environment changesthe B0 magnetic field to which this nucleus would nor-
mally be exposed in the magnet, and these resonance
frequency differences (chemical shift) allow that metabo-
lites can be distinguished from each other. Every mol-
ecule exhibits its own “fingerprint” on the chemical shift
spectrum. The exact chemical shift of a metabolite
(expressed in parts per million, ppm) is independent of
the applied field strength and characteristic of that
nucleus, aiding accurate peak identification. Clinical MRS
mainly uses endogenous signals from 1H or 31P. 1H-MRS
is the most commonly used technique because it produces
the strongest signals (due to its abundance). On its part,
31P MRS can measure the relative intracellular concentra-
tions of several phosphorus metabolites. However, it is
technically more complex and requires special hardware.
Spectroscopic measurements generally give a static picture
of tumor metabolism. In contrast, hyperpolarized MRSI
offers a dynamic evaluation of tissue metabolism. Hyper-
polarized MRSI increases the signal-to-noise ratio (SNR)
achieved with MR. When exposed to the magnetic field,
the magnetic dipole vectors of MR-active nuclei (such as
13C) are aligned either parallel or antiparallel with the ex-
ternal field, and there is usually only a small excess of par-
allel spins (the polarization percentage). However, higher
polarization values can be reached for short periods of
time via hyperpolarization, producing larger vectors and
facilitating high-SNR data and shorter acquisition times in
MRS imaging acquisitions [110].Interpretation guidelines
In clinical practice, tumor spectroscopic phenotype
can be evaluated in three ways: (a) qualitative evalu-
ation is performed by merely checking absence,
presence, or change of certain metabolites; (b) semi-
quantitative evaluation is based on two different ap-
proaches: the calculation of metabolite ratios (e.g.,
Cho + Cr/Ci ratio, which correlates significantly with
the probability of malignancy in prostate) or the
evaluation of the area under the metabolite peaks of
interest; and (c) finally, absolute quantification of the
concentration of a metabolite with the use of a ref-
erence standard for calibration.Clinical value
Spectroscopy of cancer can characterize critical tumor
metabolic pathways (including membrane turnover,
lipids, and energy metabolism) and can depict specific
tissue markers, such as N-acetyl-aspartate (NAA) (a
specific neuronal marker) or Ci. MRS technique in tu-
mors is mainly based on detecting the elevation of cer-
tain metabolites (such as Cho) or the absence or
decrease of normal metabolites (e.g., Ci in the prostate)
[108, 109–112]. However, its technical complexity, long
Table 3 Main metabolites studied in 1H-MRS and their biological significances
Metabolite Biological meaning ppm Decreased values Increased values
Cho
(total Cho-containing
compounds)
A metabolic marker cell membrane
synthesis and repair.
Related to cell density and
membrane integrity
3.22 Due to cell proliferation and to
breakdown of cell membranes.
Higher Cho levels are shown in
higher grade tumors compared
with lower-grade tumors
Cr
(from both creatine
and phosphocreatine,
often called referred to
as total creatine peak)
Reflects “cellular energetics” 3.02 Decreased phospocreatine (PCr) is an
inconstant finding in tumors.
Represents a low- energy status of
glycolisis in primary tumors (high grade
gliomas) and in metastatic tumors is
the effect of the lack of PCr in most
tissues.
Lac Glycolysis
Usually lactate is present only in
minimun amounts (i.e., in the brain)
and is not depicted using the
normal spectroscopic techniques.
Doublet
peak at
1.33
ppm
Increased Lac is the effect of the
high rate of glycolisis. Lac is an
end product of glycolysis and
increases rapidly during hypoxia
It accumulates in necrotic or
cystic areas
Lip May indicated tumor necrosis or
voxel contamination by diploic
space fat, scalp and subcutaneous
tissue
0.9 and
1.3ppm
The rise of Lip is detected in
various cellular processes such as
necrosis, growth arrest,
inflammation, malignancy and
apoptosis.
Specific metabolites in brain H-MRS
NAA A marker of neuronal and axonal
density and viability
The exact role of NAA in human
brain metabolism is uncertain. It is
postulated to be involved in
lipogenesis pathways
Largest peak in a “normal” H- MRS
brain spectrum.
2.02 Absence of neurons and axons in most
tumors but also in white matter
diseases (i.e., multiple sclerosis)
mI A glial marker located in astrocytes
Involved in osmoregulation and
volume regulation
3.56 It is a relative marker for low-
grade gliomas. Reduced in high-
grade tumors
Specific metabolites in Prostate H-MRS
Ci Normal human prostate gland
accumulates and secretes
extraordinarily high Ci levels
2.6 In prostate cancer
Ci levels fall due to consumption
of Ci to supply energy to
proliferating cells)
Ala alanine, Cho choline, Ci citrate, Cr creatine, Lac lactate, Lip lipids, mI myo-inositol, NAA N-acetylaspartate, ppm parts per million
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spectra have limited its widespread use.
– Hydrogen MRS
Characterization of intracranial tumors is a challenge
for imaging. In this setting, main 1H-MRS studies have
focused on the assessment of intracranial tumors [113].
Spectroscopy offers additional information related to
tumor proliferation and metabolic changes or neur-
onal damage, which can be used to establish noninva-
sively the diagnosis and grading of brain tumors. An
increased Cho peak along with decreased NAA is an
important diagnostic feature in brain tumors. Besides,
increased Lip seems to be secondary to necrosis and
membrane breakdown. Cancer cells also rapidlymetabolize glucose to form Lac and its levels appear
to correlate with grade and type of tumor in the
brain. Finally, a myo-inositol (MI) peak is typically
present in glial tumors at 3.5 ppm chemical shift.
1H-MRS has shown clear advantages for the assess-
ment of central nervous system neoplasms including
differentiating between tumors from other lesions,
characterizing types and grades of tumors, offering
prognostic data, planning therapy with delineation of
tumor involvement and definition of the target vol-
ume for radiation therapy, monitoring tumor re-
sponse, and detecting tumor relapse.
Technical advances allowed the use of MRS in other
organs, mainly prostate and breast [108]. PCa is charac-
terized by combinations of elevated Cho and reduced Ci.
1H-MRSI in prostate can improve tumor detection,
Fig. 16 A 56-year-old woman with an invasive ductal carcinoma of the breast. Pretherapy (a) the sagittal reformatted maximum intensity
projection (MIP) image from DCE-MRI (left) demonstrating a 5-cm enhancing mass (white arrow). MR spectrum (right) depicts a marked
choline peak (red arrow). Images obtained after chemotherapy and anti-HER2 therapy with trastuzumab (b) evidenced a residual lesion.
Sagittal reformatted maximum intensity projection (MIP) image from DCE-MRI demonstrated discrete dots of enhancement (white arrow),
while MR spectrum showed a decreased choline peak (red arrow). Tumorectomy revealed residual fibrosis without tumor cells
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siveness; and evaluation of tumor response. A meta-
analysis of the literature to assess the accuracy of MRS
in diagnosing PCa evidenced that the pooled weighted
sensitivity and specificity varied depending on the
(Cho + Cr)/Ci ratios used, ranged between 64–82 and
68–86%, respectively. Moreover, a positive correlation
was found between these ratios and the pathologic
Gleason score with a large proportion of non-
significant tumors (Gleason score ≤ 6) that do not
present abnormal metabolite ratios [114]. However, at
present, the clinical use of MRS in prostate has been
reduced due to its technical complexity. Thus, version
2 of the Prostate Imaging-Reporting and Data System
(PI-RADS v2) does not include the use of MRS.
In breast tumors, an increased Cho peak has been de-
scribed in malignant breast lesions (Fig. 16). A meta-analysis of the diagnostic performance of single-voxel
1H-MRS of the breast reported a pooled sensitivity ranged
between 71 and 74%, and a pooled specificity between
78 and 88%. However, in the case of non-mass lesions
or small masses (between 5 and 10 mm in diameter)
or foci (< 5 mm in diameter), spectroscopy was
scarcely useful [115].
– Phosphorus MRS
Malignant transformation has been found to alter the
profile of the Cho compounds (related to membrane turn-
over) and the signals from energy metabolites such as nu-
cleoside phosphates and phosphocreatine. Although
31P MRS may monitor these metabolic changes, its
clinical use has been limited due to technical comple-
xity and low sensitivity of MR systems [111, 112].
Fig. 17 A 71-year-old man with a Gleason 7 prostate cancer (PSA 6.05). A suspicious area with low ADC values was depicted in the left peripheral
area (white arrow). The hyperpolarized 13C spectra and the time course for the dynamic conversion hyperpolarized [1-13C] pyruvate to lactate
following the injection of hyperpolarized pyruvate were revaluated (top, right). Note the change of the MR spectra with the pyruvate quickly
reached a maximum at t: 57.3 s (bottom, middle) before being converted to lactate. Compared with the spectrum at t: 18.6 s (top, middle).
[Images courtesy of Kayvan R Keshari, PhD. Laboratory Head. Memorial Sloan Kettering Cancer Center]
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Currently, there is a limited clinical use of 13C hyper-
polarization in clinical studies and the majority is focu-
sing on the pyruvate metabolism in PCa (Fig. 17).
Hyperpolarized [1–13C]-pyruvate has demonstrated in-
creased lactate labeling in tumors and decreasing meta-
bolism to bicarbonate [116].Imaging tumor proliferation
Sustained proliferation is a fundamental part of cancer
development and progression. The imaging of tumor pro-
liferation may provide valuable information for tumor
diagnosis and characterization and early assessment of the
response to therapy.Biological bases of tumor proliferation
EGFR is commonly upregulated in cancers. EGFR
over-activates downstream pro-oncogenic signaling path-
ways, including the Ras-Raf–mitogen-activated protein
kinase (MAPK) pathway and the PI3 kinase (PI3K)–Akt–
mechanistic target of rapamycin (mTOR) pathway. These
pathways activate cell growth, proliferation, and survival.Imaging approaches to tumor proliferation
Noninvasive imaging-based assessment of cellular prolif-
eration in cancer is mainly based on radiotracers that
track the thymidine salvage pathway of DNA synthesis.
– PET imaging of tumor proliferation
[18F]-3-fluoro-3-deoxythymidine (FLT) is a nucleoside-
analog imaging agent that presents intracellular accumu-
lation of the tracer during the S-phase of the cell
cycle through the action of the thymidine kinase-1
(TK1). Since this kinase is primarily expressed in
dividing cells, FLT uptake is essentially limited to
proliferating cells. FLT uptake has been shown to
correlate with Ki-67 expression, a classic marker of
tumor proliferation [117]. FLT has been rarely used
for tumor response evaluation due to the limited
knowledge of the factors determining FLT uptake
and therapy-induced changes of its retention. Never-
theless, published data suggest that decreased radio-
tracer uptake generally reflects the effects of
anticancer therapies, although it should be taken
into account that drugs impacting TK1 (such as
antifolates) may induce a flare effect.
García-Figueiras et al. Insights into Imaging           (2019) 10:28 Page 25 of 35Other radiotracers (Cho-PET) and different imaging
techniques (MRSI or DWI) may also offer an indirect
assessment of tumor proliferation. Cho metabolism is
involved in the synthesis of Lip required for cell mem-
brane turnover in tumor proliferation. In this setting,
MRSI Cho peak and Cho-PET uptake may indirectly
evaluate the cell proliferation. Thus, a number of studies
have found significant correlations between the SUV of
Cho-PET or Cho peaks on MRSI and Ki-67 proliferation
scores. Changes in Cho metabolism are being used in on-
cology for diagnosis, prognosis, and monitoring response.
However, it is also necessary to consider that Cho is not a
specific cancer tracer (e.g., normal testicles show elevated
Cho peaks and granulomatous LNs may present increased
uptake on Cho-PET).
DWI may also reflect other histopathological features,
such as proliferation potential. However, based on a recent
meta-analysis, the correlation of DWI-derived parameters
and tumor proliferation based on the expression of cell
proliferation markers (e.g., Ki67) showed a great variability
depending on tumor type [118, 119].
Evaluation of tumor vasculature-angiogenesis
Tumor angiogenesis is the process of developing new
blood vessels in order to supply oxygen and nutrients to
support the growth of tumors. Angiogenesis is a key
cancer hallmark required for invasive tumor growth and
metastasis development and constitutes a basic target in
the therapy of cancer. Imaging modalities used to eva-
luate tumor neovasculature mainly include CT, MRI, or
US [120–125]. All of them have strengths and weak-
nesses regarding availability, sensitivity, accuracy, bio-
logical significance of the obtained data, technical
reproducibility, methods for image quantification, pro-
vided parameters, and the anatomical areas that can
be imaged.
Biological bases of angiogenesis
Most solid tumors arise as avascular cellular masses that
exclusively depend upon oxygen delivery by diffusion.
When tumor size exceeds oxygen diffusion distances, re-
gions of hypoxia will develop within the mass. This fea-
ture causes the secretion of angiogenic factors
(particularly the vascular endothelial growth factor,
VEGF), which activate the angiogenic switch. However,
tumor vasculature is highly abnormal. Tumor vessels are
often larger but less numerous and more ineffective than
those of normal tissues. Besides, tumor blood vessels are
heterogeneous and abnormal with regard to organization,
function, and structure. The combination of these vascular
characteristics causes that the overall BF tended to be sig-
nificantly lower in tumors and the subsequent develop-
ment of hypoxia. Unfortunately, imaging techniques used
in clinical practice usually check the effects of angiogenesison tumor vasculature, not the angiogenic process itself
[120–126].
Technical features
Imaging plays a central role in the clinical evaluation of
angiogenesis. Anatomical imaging remains the mainstay
for tumor evaluation pinpointing sites of enhancement
and evaluating the degree of enhancement. New tech-
nologies, such as dual-energy CT, may have an added
value over conventional CT imaging for tumor assess-
ment. In this setting, quantitative iodine concentration
maps obtained with spectral CT have shown good corre-
lations with conventional CT perfusion measurements
in different tumor types [127]. Imaging techniques can
also characterize functional abnormalities of vessels and
can assess vascular heterogeneity. Different imaging
techniques with and without the use of exogenous con-
trast media have been used for the functional evaluation
of tumor vasculature. DCE techniques including CTP,
DCE-US, DCE-MRI, or DSC-MRI are the most common
imaging methods for assessing tumor vasculature [120–
126]. These imaging techniques acquire a series of im-
ages through a region of interest before, during, and
after the intravenous injection of a contrast agent. DCE
techniques may provide information related to tumor
vessels function (perfusion or permeability). Data ob-
tained depend on multiple features including imaging
technique, the type of contrast agent, and the method of
analysis. On its part, IVIM and ASL constitute the main
non-contrast-enhanced imaging techniques for the
evaluation of tumor vasculature. CTP evaluates temporal
changes in tissue attenuation following the intravenous
administration of contrast media. In this context, iodine
concentration changes may represent an indirect reflec-
tion of tissue vascularity and vascular physiology [126]
(Fig. 18). On its part, DCE-US with gas-filled microbub-
bles offers potential for the evaluation of tumor perfu-
sion. Microbubbles flood across tumor capillary bed and
the gas they contain contracts and expands under the al-
ternating higher and lower pressure phases of the US
beam, producing harmonics that can be detected for
extracting kinetic characteristics from DCE-US echo in-
tensity (which is directly related to local vascularization
and contrast-agent concentration) versus time data
[128]. DCE-MRI calculates tissue perfusion parameters by
evaluating T1 shortening induced by a gadolinium-based
contrast agent bolus as it distributes in the tumor
vasculature and leaks across permeable vessels. The
resulting signal intensity–time curve reflects a com-
posite of tissue perfusion, vessel permeability, and
extravascular-extracellular space and can be analyzed
to derive a number of potential biomarkers of the vascular
microenvironment. DSC-MRI or T2*-weighted DCE is
based on the local magnetic inhomogeneities that arise on
Fig. 18 Perfusion CT exam in a 42-year-old man with a metastatic renal carcinoma. Blood flow (BF), blood volume (BV), and permeability (PS)
parametric maps evidenced the heterogeneity of the functional status of the vasculature within the tumor with several combinations of the
obtained parameters (top-left) and clear differences between the time density curves coresponding to the peripheral areas of viable tumor with
increased BV, BF, and PS (a) with a wash-in/wash-out pattern and the central necrotic necrotic areas (a)
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netic susceptibility, leading to signal reduction on T2 or
T2*-weighted gradient-echo sequences. The transient
signal loss induced by the pass of the contrast agent
across tissue vascular network is proportional to the
local BV and BF. DSC studies are basically limited to
the evaluation of brain tumors. Finally, ASL is based
on the principle of magnetically labeling inflowing ar-
terial blood protons inverting the bulk magnetization
of the blood water protons prior to their entry into
the tissue of interest. A control image, in which the
blood water magnetization is not inverted, is also ac-
quired. The signal difference between labeled and
control images will be proportional to BF. Quantifica-
tion allows for regional and global assessments of
perfusion. ASL is being applied in brain imaging
(Fig. 19) [129].Interpretation guidelines
Many features need be considered in the acquisition and
analysis of DCE exams, including the organ studied and
the clinical setting. The characteristics of perfusion data
acquisition (temporal resolution, length, etc.) and the
model of analysis of enhancement kinetics directly influ-
ence the calculation of vascular parameters. Analysisand interpretation of DCE-imaging data can be per-
formed with different approaches [120, 121]:
– Qualitative analysis: Visual assessment of pre- and
postcontrast images, or of the shape of the time-
intensity curves (TIC) represents the most simple
way of analysis. Curve characteristics, including
the speed of the filling phase, the maximum peak
intensity, and the morphology following the peak
of enhancement (persistent increase, plateau, or
washout), are evaluated. This approach has shown
clinical utility for the characterization of breast,
soft-tissue, and prostate tumors, although does not
produce a quantifiable index.
– Semiquantitative analysis: This type of evaluation is
based on performing a direct analysis of changes in
SI using semiquantitative indices. Main descriptors
that characterize the shape and structure of the
curves include time to peak enhancement, initial
area under the curve (IAUC), maximum enhancement,
etc. These parameters have been used in the clinical
evaluation of brain, breast, and prostate tumors.
Unfortunately, they do not present a clear defined
relationship with tumor physiology.
– Quantitative analysis: The combination of DCE
imaging with mathematical modeling of the contrast
Fig. 19 Brain perfusion in a 55-year-old woman with a meningioma.
a An axial fluid attenuation inversion recovery (FLAIR) image of the
brain demonstrated a hyperintense extra-axial insular lesion (white
arrow). Both (b) dynamic susceptibility contrast (DSC)-MRI and (c)
arterial spin labelling (ASL) parametric maps demonstrated and
increased perfusion in the mass. Comparison to normal brain
parenchyma evdenced a higher decrease in MR signal intensity
curves during the first-pass of the contrast bolus (b, blue curve)
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structural and functional changes in tumor
microvasculature. Measured TICs must be
converted into concentration of contrast–time
curves and modeled in a pixel-wise fashion to create
functional maps of vascular parameters. In general,
the complexity of the quantitative analysis and the
lack of consensus have limited its applications to
clinical trials in academic centers.
Clinical value
The angiogenic phenotype shows a great heterogeneity
among different type of tumors and even in the same
tumor type or in different regions of the same tumor.
Imaging-based phenotypes are important features for the
decision-making process in oncology, including tumor
diagnosis, characterization and grading, biopsy guiding,
staging, prognostic biomarker and response prediction,
therapy planning, assessment of treatment response, de-
tection of relapsing tumor, and development of new can-
cer drugs. Tumor vasculature provides an attractive
target for anticancer therapies [120, 121, 126].
DCE-imaging is now frequently used in early clinical
trial assessment of angiogenic inhibitors [43, 126, 130].
In these patients, therapy response is associated to a sig-
nificant decrease in perfusion and permeability-related
parameters. Moreover, an early reduction in vascular pa-
rameters following therapy is usually associated to an
improved patient’s outcome.
Imaging cell death in cancer
Imaging programmed cell death would be useful both in
clinical care and in drug development.
Biological bases of cell death
Cell death has been classified, on the basis of mor-
phologic criteria, as programmed cell death (apop-
tosis) or non-regulated (necrosis) [131]. Necrosis is
characterized by loss of plasma membrane integrity,
which frequently causes marked inflammation, tissue
destruction, and fibrosis. On its part, apoptosis is ac-
companied by a series of complex morphological
changes, including cell shrinkage, chromatin conden-
sation, and formation of apoptotic bodies. Apoptotic
bodies are subsequently ingested by adjacent cells and
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response. Apoptosis is also characterized by several
molecular alterations, including the externalization of
phosphatidylserine to the outer leaflet of the plasma
membrane bilayer and the activation of caspases
[132]. Phosphatidylserine exposure by dying cells has
been evaluated with radiolabeled annexin V. However,
it has not become routine in clinical practice.Technical features
Radiotracers and modalities for the imaging of apoptosis
include phosphatidylserine-binding agents (annexin V)
and MR-based imaging with the assessment of mobile
lipids and Cho with 1H-MRS and DWI [131–134] (Figs. 6
and 7).Fig. 20 A 70-year-old woman with high-grade serous ovarian cancer who
fluorodeoxyglucose uptake [FDG SUV] is showed) and MRI, which included
(images on the left) showing a primary ovarian mass as well as multiple pe
“habitat” map of the implant in the cul-de-sac was performed (right) conta
from each cluster represented by a different color on the habitat map dem
heterogeneity observed on imagingClinical value
There is a limited use of clinical imaging in the
evaluation of cell death, although MRI seems to be a
promising tool. Apoptosis and necrosis exhibited dif-
ferent changes on MR exams including T1- and
T2-weighted sequences, DWI, and MRS [133, 134].
Necrosis secondary to therapy is accompanied by an
early increase in ADC values, while apoptotic treat-
ments do not cause significant ADC changes [133].
In the case of 1H-MRS, this technique demonstrates
apoptosis- and necrosis-specific changes on cell mo-
bile Lip peaks [132].
Imaging of cancer heterogeneity
Tumors are biologically heterogeneous at the morpho-
logic, histological, and genetic levels. Imaging has begununderwent FDG-PET/CT (standardized uptake value map of the
T2, diffusion (DWI), and dynamic contrast-enhanced (DCE) sequences
ritoneal/serosal implants including in the cul-de-sac. A composite
ining three clusters derived from PET and MRI data. Tissue sampling
onstrated genomic heterogeneity underpinning the phenotypic
Fig. 22 Whole-body DWI evaluation in a 72-year-old man with metastatic prostate cancer treated with (docetaxel + prednisone). A comparison
between images pre (left) and posttherapy (right) demonstrated that tumor volume decreased (1280 cm3→ 640 cm3) and mean ADC moved
from 0.7 to 1.61 confirmed an increasing % of voxels at higher ADC values after therapy consistent with reductions in cellularity due to tumor
necrosis. However, tumor response was heterogeneous in this patient and there were some anatomical areas that presented a limited tumor
response (black dotted circle on lumbar spine and black arrows)
Fig. 21 Colorectal cancer liver metastasis in a 56-year-old man. FDG-PET (left) and b500 diffusion-weighted (middle) images demonstrated the
presence of a mismatch between the obtained parameters. Note that the size of the FDG abnormality is smaller than the diffusion one (black
arrow) (right). Tumor biology may explain this feature. Higher FDG uptake occurs at the edge of the necrotic cavity (white arrow) which is of
relative low SI on b500 image. The edge of the necrotic cavity usually represents an area of relative tumor hypoxia, which may promote a high
metabolic activity (vascular metabolic-mismatch). On its part, the periphery of the mass generally presents good perfusion and it is the most
cellular area of the tumor, explaining the restricted diffusion at this level
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eity between (intertumor) and within tumors (intratu-
mor) of a given patient.
Biological bases
Genetic variation is undoubtedly the most established
foundation of both intra- and intertumor heterogeneity.
However, other features such as epigenetics or tumor
microenvironment also play a role on heterogeneity [135].
Intertumoral heterogeneity has resulted in the classifica-
tion of tumor subtypes, which are characterized by dis-
tinct morphology, functional, molecular and genetic
profiles, and expression of specific markers. On its part,
intratumoral heterogeneity manifests as variations within
the tumors (Fig. 20). Distinct tumor genotypes and/or
phenotypes usually associate divergent biological behav-
iors, and this circumstance may have prognostic signifi-
cance and may influence response to therapy. In general,
the degree of intratumor heterogeneity tends to in-
crease as tumors grow and greater heterogeneity tends
to be associated to a relatively poor clinical outcome
and resistance to therapy.
Technical features
Tumor spatial and temporal heterogeneity is a critical
oncologic feature that can be reflected in medical images
and interpreted based on different approaches: (1) evalu-
ating simple qualitative descriptors (e.g., tumor margin
or shape); (2) quantifying parameter distributions with
histogram-based analysis (discarding spatial relationship
between voxels and treating data as a list of continuous
variables); (3) quantifying spatial complexity (e.g., tex-
ture, fractal, or cluster analysis); (4) grouping voxels with
common biological features (parcellation); or (5) analysis
assessing quantitatively the spatial distribution of para-
meters (e.g., parametric maps) (which tend to derive
average parameter values), etc. [3, 135–139].
Clinical value
The advantage of diagnostic imaging techniques in the
assessment of tumor heterogeneity is their noninvasive
nature and the fact that the whole tumor may be eva-
luated, whereas histological techniques are invasive and
limited to a discrete set of tumor samples. There is a
growing evidence that qualitative or quantitative eva-
luation of heterogeneity presents clinical advantages for
screening, diagnosis, grading, staging, and assessment of
response therapy in tumors [138]. Unfortunately, many
parameters, such as kurtosis, have no clear biological
correlate making biological validation difficult. More-
over, in order to improve a global assessment of tumor
heterogeneity, whole-body imaging techniques (e.g., PET
or WB-DWI) offer an ideal solution as they allow a
global assessment of tumor burden.Future trends of imaging in cancer
There are extraordinary future opportunities for imaging
techniques in tumor biology evaluation, including the
development of imaging biomarkers and radiomics/
radiogenomics, the use of multiparametric analysis and
artificial intelligence, and theranostic. To date, most
research has been focusing on validating biomarkers
extracted from tissue or blood samples, which has im-
proved patient stratification and assisted oncologic drug
development. Imaging techniques can evolve into clini-
cally useful biomarkers for tumor assessment and evalu-
ation of therapy response. The advantages of imaging
are its versatility, its widespread disponibility, its capabi-
lity of evaluating whole tumor burden, and its relatively
noninvasive nature [140–144]. Adequate quantification
of imaging biomarkers is of paramount importance
when extracted data are going to be used in patient
management. In this setting, data must be reproducible
and the technology used to extract them must be stan-
dardized. Biomarkers precise a complex process of vali-
dation and qualification [140, 143]. On the other side, in
recent years, imaging has been boosted by the techno-
logical development generating a large volume of data.
Such information has increased in complexity and may
offer prognostic value and may reveal meaningful infor-
mation for decision-support in cancer diagnosis and
treatment. Radiomics refers to the extraction and quan-
titative analysis of tumor characteristics from medical
images. On its part, radiogenomics investigates the rela-
tionship between imaging features and gene expression.
The -omic approach is based on numerical calculus and
computer science methods, allowing the management and
analysis of a very large number of variables for each sample
and modality. There is a rapid increase in the number of
publications that have highlighted the utility of imaging
-omics in many different tumor types and based on dif-
ferent imaging techniques [145–155]. Radiomics and
radiogenomics approaches may show clinical utility for
assisting in cancer diagnosis, assessment of tumor
aggressiveness, response assessment, and evaluation of
patients’ outcome. Integrating (quantitative) imaging
data with other relevant information (clinical, patho-
logical, etc.) and multi-omics (genomics, proteomics,
and metabolomics) will be essential for unraveling
tumor heterogeneity and making real-time clinical
decisions for patients in personalized medicine. How-
ever, this process still necessitates improvement and
standardization in order to achieve routine clinical
adoption. In this scenario, computers may be useful
tools for the assessment of tumor characteristics and
for the evaluation of therapy response. Computers can
learn (machine learning) to extract meaningful patterns
(including patterns that are beyond human perception)
by processing massive datasets (big data) through
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rect algorithm mistakes by training. Machine learning
algorithms are just useful components of computer-aided
diagnosis and decision support system in oncology.
Imaging representation and interpretation of tumor biol-
ogy will require computational models to understand and
predict the complex nonlinear dynamics that result in
combinations of imaging features [156–158]. 3D printing
is also an emerging computer-based technique that may
be useful in oncology for research, surgical planning
(using an exact 3D model of the patient’s organs to prac-
tice a procedure), device designing and manufacturing,
and tissue or organ replacement [159]. The analysis of
multi-dimensional imaging datasets is also increasingly
required for imaging tumor phenotype. The correlation
between imaging features obtained with different tech-
niques must be explored for understanding the underlying
tumor biology (Fig. 21). Significant differences in vascular,
physiological, and metabolic characteristics have been
identified in metastatic and nonmetastatic cancers. In this
setting, high glycolytic activity and poor perfusion (vascu-
lar-metabolic mismatch) result in an aggressive tumor
phenotype [160]. Finally, advances in the understanding of
cancer biology together with developments in diagnostic
technologies, and expansion of therapeutic options have
all contributed to the concept of personalized cancer care
with accurate and specific targeting of cancer cells. Thera-
nostics is the systematic integration of targeted diagnostics
and therapeutics. Imaging may select the therapeutic
choice and may monitor subsequent changes in the bio-
logical characteristics of the tumor [161, 162].
In conclusion, clinical imaging has tremendous poten-
tial in the evaluation of a wide spectrum of biological
tumor characteristics at all stages of a cancer patient’s
management and in drug discovery. Imaging techniques
have also the ability to show the spatial and temporal
heterogeneity of tumors (Fig. 22). In the time of preci-
sion oncology, clinical imaging represents a basic
decision-making tool in cancer patients.
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